80 likes | 92 Views
Hematological malignancy is a type of cancer that affect the bone marrow, blood, and lymph nodes. They include several forms of myeloma, leukemia, and lymphoma. According to an industry report in 2011, Hematological malignancies constituted 9% of all newly diagnosed malignancies in the U.S. specifying that lymphomas are more prevalent than myeloma or leukemias.
E N D
Hematologic Malignancies Therapeutics MarketSet to Exceed USD 87.0 Billion by 2025 “Hematologic Malignancies Therapeutics Market [By Type (Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia), Lymphoma, Multiple Myeloma, and Others); By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others); and By Regions (North America - U.S., Canada; Europe - Germany, UK, France, Italy; Asia-Pacific - China, India, Japan, Australia; Latin America - Brazil, Mexico; Middle East & Africa)]: Market size & Forecast, 2018 – 2025”
Hematologic Malignancies Therapeutics Market Estimate & Forecast to 2026 The Global Hematologic Malignancies Therapeutics Market Size is anticipated to reach over USD 87.0 Billion by 2025 according to a new research published by Polaris Market Research. Hematological malignancy is a type of cancer that affect the bone marrow, blood, and lymph nodes. They include several forms of myeloma, leukemia, and lymphoma. According to an industry report in 2011, Hematological malignancies constituted 9% of all newly diagnosed malignancies in the U.S. specifying that lymphomas are more prevalent than myeloma or leukemias. Excluding Hodgkin’s lymphoma as well as acute lymphocytic leukemia, these types of malignancy are usually related to growing age. Hence, considering the aging worldwide population, malignancy type is more probable to become more prevalent. The global Hematologic Malignancies Therapeutics Market growth is majorly driven by the increasing focus on development for novel treatments and growing occurrence of blood cancer. Currently, blood malignancies are the second most leading cause of cancer deaths and the 5th most common cancer. The three most common types of blood cancers are multiple myeloma leukemia, and lymphoma. Each year, approximately 400,000 people are diagnosed with lymphoma and more than 300,000 people are diagnosed with leukemia globally. In addition, inventions of novel drugs for blood cancer and its regulatory approvals are anticipated to bolster the market growth. .
Hematologic Malignancies Therapeutics Market Scope Request for sample
Hematologic Malignancies Therapeutics Market Estimate & Forecast to 2026 The Global Hematologic Malignancies Therapeutics Market is segmented on the basis of type, therapy, and geography. Based on type, the market is segmented into leukemia, lymphoma, multiple myeloma, and others. The leukemia is further segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. On the basis of type, leukemia was estimated to dominate the market. The major market share is due to availability of products such as Imbruvica, Rituxan, and Glivec, which are estimated to be the highest revenue generating drugs. On the basis of therapy, the global Hematologic Malignancies Therapeutics Market is segmented into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others. Amongst all the therapies, chemotherapy is the most commonly used treatment with a particular drug or combination of drugs used. Some major key players in global Hematologic Malignancies Therapeutics Market includes Pfizer, Inc., F. Hoffmann-LA Roche ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson Services, Inc., and Takeda Pharmaceutical Company limited among others. The object of the key market players is to deliver better chronic care administration while keeping the cost low. In addition, the companies are concentrating on producing easy-to-use monitoring devices that can aid patients to accomplish conditions including diabetes or heart diseases better by avoiding costly medical processes. Browse Complete Report
Hematologic Malignancies Therapeutics Market Size Request for TOC
Hematologic Malignancies Therapeutics Market Study – Engagement Options Buy Now – Click Here! Buy now & have immediate access to premium insights Purchase Report Sections – Click Here! Regional analysis Segmentation analysis Industry outlook Competitive landscape Speak To Analyst – Click Here! Get your doubts clear Schedule a call with our analyst before making any decision Request For Sample Pages – Click Here! Get free sample pages Understand report structure Unmask data for validation
About Us Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to e present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers. Web: www.polarismarketresearch.com Official Blog: http://polarismarketresearch.blogspot.com
Thank You! Contact Us : Polaris Market Research30 Wall Street8th Floor, New York City, NY 10005,United States E mail Id: sales@polarismarketresearch.com Phone: +1-646-568-9980